Dinamika pendapatan YoY sajrone rolas wulan kepungkur: Viridian Corp (VRDN)

Tandha merek Viridian Corp (VRDN)

Viridian Therapeutics (VRDN) has established itself as a bold innovator striving for dominance in ophthalmology. The firm's success relies on regulatory approvals and the results of new drug trials; however, the risk of trial failure and high capital expenditure remain critical factors. This 12-month YoY revenue growth chart on GURU.Markets visualizes a trend where the -62.40 metric determines the parameter status.

Wutah dodolan YoY (TTM): Viridian Corp (VRDN) kanggo 11.02.2024 - 18.11.2026

viridiantherapeutics.com (VRDN) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:
- indikator kapitalisasi bursa perusahaan:
Analisis kabeh metrik perusahaan:Viridian Therapeutics - VRDN
Produk mawa merek Viridian Therapeutics

For the ophthalmology biotech leader Viridian Therapeutics (VRDN), the 12-month YoY sales change chart serves as an indicator of the commercial realization of scientific achievements in the therapy of endocrine pathologies. This metric calculates the percentage shift in trailing twelve months (TTM) revenue, allowing investors to track the current market consensus and assess business scaling rates without time gaps between quarterly reports.